The Australian Pancreatic Cancer market size stood at around USD xx billion in 2019 and is projected to reach USD xx billion by 2028, exhibiting a CAGR of xx% during the forecast period.
Pancreatic cancer was the 8th most diagnosed cancer in Australia in 2016. It is estimated that it will remain the 8th most diagnosed cancer in 2020. Pancreatic cancer happens when uncontrolled cell growth begins in a part of the pancreas. Tumors develop, and these interfere with the way the pancreas works. pancreatic cancer therapeutics and diagnostics involve procedures for the successful diagnosis and treatment of pancreatic cancer. Moreover, the rising number of patients results in advancements in molecular biology and chemical drug formulation. Thus, a huge pool of patients who have pancreatic cancer is expected to increase the growth of the pancreatic cancer therapy market over the forecast years.
The market studied is majorly driven by the factors such as the increasing prevalence of pancreatic cancer, increasing demand for diagnostic tests and treatment of this disease. As a result, many governments and non-profit organizations have taken initiatives to spread awareness regarding pancreatic cancer. Moreover, technological advancements have in diagnostics and treatment have led to solutions that more efficient. These are the major factors that have propelled the market growth.
The last decade has seen major advances in DNA sequencing technologies, with tumor gene sequencing now being recommended in expert guidelines as a standard for all patients with metastatic disease. Olaparib, a targeted drug, was approved in late 2019, for certain patients with germline BRCA-mutated pancreatic cancer.
Pancreatic cancer was the 8th most diagnosed cancer in Australia in 2016. It is estimated that it will remain the 8th most diagnosed cancer in 2020. In 2016, there were 3,378 new cases of pancreatic cancer diagnosed in Australia (1,745 males and 1,633 females). In 2020, it is estimated that 3,933 new cases of pancreatic cancer will be diagnosed in Australia (2,015 males and 1,918 females).
In 2018, there were 3,077 deaths from pancreatic cancer in Australia (1,596 males and 1,481 females). In 2020, it is estimated that there will be 3,300 deaths (1,716 males and 1,584 females).
In 2012–2016, individuals diagnosed with pancreatic cancer had an 11% chance (11% for males and 11% for females) of surviving for five years compared to their counterparts in the general Australian population. Between 1987–1991 and 2012–2016, five-year relative survival for pancreatic cancer improved from 3.2% to 11%.
At the end of 2015, there were 1,955 people living who had been diagnosed with pancreatic cancer that year, 3,886 people living who had been diagnosed with pancreatic cancer in the previous 5 years.